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Background: It has been suggested that bilirubin has an inverse association with cardiovascular disease (CVD) due to its 
antioxidant properties. However, there are few data regarding the relationship between serum total bilirubin (sTB) and 
risk factors for CVD in Koreans. This study aimed to evaluate the relationship between sTB and high sensitivity C-reactive 
protein (hsCRP), which is an independent risk factor for CVD.
Methods: We performed a cross sectional study in 6,800 men who were examined at a health promotion center at a 
university hospital in Korea between May 2005 and June 2006. We grouped the subjects according to values of serum 
hsCRP (above or below 1.0 mg/L) and compared the characteristics of the two groups. To evaluate the relationship 
between sTB and hsCRP , we classiﬁ  ed the subjects according to quartile values of sTB. Multivariate logistic regression 
analyses were used to analyze the relationship of levels of sTB and hsCRP after adjusting for known risk factors for CVD.
Results: Serum hsCRP was signiﬁ  cantly associated with body mass index (BMI), smoking, diabetes, hypertension, fasting 
plasma glucose, systolic blood pressure, alanine aminotransferase, and total cholesterol/high density lipoprotein (TC/
HDL-C) ratio, but not with age or alcohol use. As levels of sTB increased, there was a decrease in age, numbers of smokers, 
BMI, and TC/HDL ratio. Compared to the lowest quartile of sTB, levels of hsCRP decreased with odds ratios of 0.82 (95% 
CI, 0.71 to 0.96), 0.75 (95% CI, 0.65 to 0.88), and 0.63 (95% CI, 0.54 to 0.74) in the 2nd, 3rd, and 4th quartiles of bilirubin, 
respectively.
Conclusion: Bilirubin may be inversely associated with hsCRP.
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INTRODUCTION
Atherosclerosis (AS) is a vascular disorder in which the 
arterial walls thicken as a result of the accumulation of fatty 
materials. AS is also a chronic inflammatory disease caused 
by the deposition of activated lymphocytes and macrophages 
and is promoted by low-density lipoproteins. When AS 
progresses, cytokines such as interleukin-6 (IL-6), tumor 
necrosis factor-α (TNF-α), and C-reactive protein (CRP) 
increase.
1,2) High sensitivity CRP (hsCRP) is associated with 
instability of atheromatous plaque and is a predictive indicator Kiwoong Yu, et al: Association of Bilirubin with C-reactive Protein
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for cardiovascular morbidity.
3) Th   us, an elevated level of hsCRP 
is associated with a risk of myocardial infarction in older people, 
patients with angina who have a high risk of cardiovascular disease 
(CVD), and also in healthy adults.
4) Additionally, similar to serum 
total cholesterol and the ratio of serum total cholesterol to high 
density lipoprotein (TC/HDL-C), an elevated level of hsCRP is 
an independent predictive indicator of cardiovascular morbidity
5) 
and is a stronger predictive risk factor for CVD than classical risk 
factors.
6) Schwertner et al.
7) reported that serum total bilirubin 
(sTB) was inversely correlated with risk of CVD, and Hunt et al.
8) 
found that the patients who had lower levels of sTB had up to an 
80% increase in the risk of CVD compared to patients who had 
higher levels of sTB. However, there are few hypotheses about 
the relationship between sTB and CVD. According to a previous 
Korean study, sTB is a valuable indicator for AS of coronary 
arteries in patients with asymptomatic type II diabetes mellitus 
(DM). But there is little research regarding the relationship 
between sTB and CVD in Koreans. Therefore, we conducted 
the present study to analyze the relationship between sTB and 
hsCRP in middle-aged Korean men who visited a hospital health 
promotion center.
METHODS
1. Study Subjects 
Our study subjects were 19,747 middle-aged Korean men 
who visited the Health Promotion Center of Kangbuk Samsung 
Hospital between May 01, 2005, and June 30, 2006. Subject age 
ranged from 40 to 59 years old. Of the 19,475 potential subjects, 
we excluded 12,475 subjects who had multiple medical problems 
or abnormal laboratory findings. Subjects with any of the 
following were excluded: chronic diseases such as malignancies, 
chronic liver disease, and CVD, including ischemic heart disease, 
cerebral infarct, and peripheral vascular disease; infectious or 
inflammatory diseases; abnormal liver function, defined as 
an elevation of aspartate aminotransferase (AST) or alanine 
aminotransferase (ALT) three times more than the upper normal 
limits, a level of serum albumin lower than 3.5 mg/dL, or sTB 
above 2.0 mg/dL (34.2 μmol/L, SI unit),
9) abnormal fi  ndings in 
the hepatobiliary tract on sonography; acute infectious diseases 
such as acute respiratory infection and acute hepatitis or chronic 
infl  ammatory disease such as osteoarthritis, rheumatoid arthritis, 
gouty arthritis, asthma, and infl  ammatory bowel disease; level of 
hsCRP greater than 5 mg/dL; white blood cell count greater than 
10,000/μL; rheumatic factor titer of more than 1:80; or the use 
of any medication for more than one week within one year. Aft  er 
applying these exclusion criteria, we enrolled 6,800 middle-aged 
Korean men as fi  nal subjects. 
2. Data Collection 
Each subject was asked to fi  ll out a self-report questionnaire 
and participate in an interview with a physician who collected a 
history including medical problems, medications, and life habits 
such as smoking status and alcohol consumption. Smoking status 
was recorded as current smoker, ex-smoker, or non-smoker. 
Alcohol consumption was recorded as frequent (more than one 
time per week) or infrequent (less than one time per week). A 
nurse measured the body mass index [BMI, weight (kg)/height 
(m)
2] and blood pressure (BP) of each subject. Laboratory 
tests, which were performed aft  er subjects had fasted for at least 
10 hours, included serum hsCRP, sTB, fasting plasma glucose 
(FPG), total cholesterol (TC), HDL-C, albumin, AST, and ALT. 
A physician determined whether each subject had hypertension 
(HT) or DM by medical history. According to the American 
Heart Association and Centers for Disease Prevention, a person 
who has a level of hsCRP above 1.0 mg/L is at more than average 
risk of CVD and a person with an hsCRP level below 1.0 mg/L 
is at lower risk of CVD.
10) Th   erefore, we divided patients into two 
groups according to whether their hsCRP was above or below 1.0 
mg/L.
3. Statistical Analyses 
We classifi  ed all of the subjects into two groups according to 
their hsCRP level (above or below 1.0 mg/L) and compared each 
risk factor for CVD between the two groups. In addition, all of the 
subjects were classifi  ed into quartiles (25th, 50th, 75th percentile) 
according to levels of sTB and analyzed for associations between 
sTB level and risk factors for CVD. Clinical factors were expressed 
as mean ± standard deviation for continuous variables and as 
numbers and percentages for categorical variables. Student’s t-test 
or ANOVA and chi-square tests were used to analyze continuous 
and categorical variables, respectively.
To estimate the odds ratio (OR) and 95% confi  dence interval Kiwoong Yu, et al: Association of Bilirubin with C-reactive Protein
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(CI) of increased hsCRP according to sTB levels, we used 
multivariate logistic regression models to adjust for other factors. 
Th   e group that had the lowest level of sTB was used as a reference 
group. We used three multivariate logistic regression models 
according to the clinical factors included in the analysis. Th  e  fi  rst 
model included only age (greater or less than 45 years old). Th  e 
second model included smoking status and alcohol consumption 
as well as age. In the third model, the following factors were added 
to the second model: serum ALT (greater or less than 40 mg/
dL), FPG (below 100 mg/dL, 100 mg/dL to 125 mg/dL, and 
above 126 mg/dL), systolic BP (below 120 mm Hg, 120 mm Hg 
to 139 mm Hg, and above 140 mm Hg), and serum TC/HDL-C 
ratio (25th, 50th, 75th percentile). All analyses were performed 
using SPSS ver. 16.0 (SPSS Inc., Chicago, IL, USA). Statistical 
signifi  cance was set at P-values and confi  dence intervals of < 0.05 
and 95%, respectively.
RESULTS
Table 1 shows the baseline characteristics of the 6,800 study 
subjects. Subjects were classified into two groups: the low-risk 
group (n = 5,100; hsCRP < 1.0 mg/L) and the average to high-
risk group (n = 1,789; hsCRP > 1.0 mg/L) for CVD. Compared 
to the average to high-risk group, the low-risk group had lower 
body mass index (BMI); lower prevalence of current smokers and 
patients with DM and HT; and lower levels of FPG, systolic BP, 
ALT, and TC/HDL-C ratio (all P < 0.001). Additionally, the low-
risk group had a lower level of sTB than the average to high-risk 
group (P = 0.03).   
Table 2 shows the baseline characteristics of the four sTB 
groups (quartiles), which were analyzed using ANOVA and chi-
square tests. Th   e mean age of the group with the lowest sTB (sTB 
< 13.58 μmol/L) was significantly lower than the highest sTB 
group (sTB > 20.70 μmol/L) (44.31 ± 3.95 years vs. 44.09 ± 3.74 
years, P < 0.001). BMI, prevalence of current smokers, and the 
TC/HDL-C ratio signifi  cantly decreased with increasing levels of 
sTB (P < 0.012 and P = 0.01, respectively). Levels of hsCRP also 
signifi  cantly decreased with increasing levels of sTB (P < 0.001). 
However, the frequency of alcohol consumption, percentage of 
patients who had DM or HT, levels of FPG, systolic BP, and ALT 
were not signifi  cantly diff  erent among the four groups. 
We performed a multivariate logistic regression analysis to 
estimate ORs and 95% CIs of increased hsCRP according to 
quartiles of sTB levels and used three logistic regression models 
to adjust for various factors (Table 3). In model I, which adjusted 
only for age, when compared to the lowest quartile of sTB, the 
ORs (95% CI) for hsCRP in the 2nd, 3rd, and 4th sTB quartiles 
were 0.82 (0.70 to 0.95), 0.73 (0.63 to 0.85), and 0.61 (0.52 to 
0.71), respectively, and these were statistically signifi  cant (P for 
trend < 0.001). In both model II (adjusted for age, smoking status, 
and alcohol consumption) and model III (adjusted for BMI, ALT, 
FPG, systolic BP, and TC/HDL-C ratio as well as the factors in 
Table 1. Mean and prevalence (%) of baseline variables according 
to hsCRP level. 
hsCRP (mg/L) (n = 6,800)
Low risk (<1.0)
(n = 5,011)
Average to 
high risk (≥1.0)
(n = 1,789)
P-value*
Age (y) 44.13 (3.78) 43.99 (3.61) 0.19
BMI (kg/m
2) 24.05 (2.43) 25.23 (2.64) <0.001
Smoking status <0.001
Non-smoker 1,593 (31.8) 456 (25.5)
Ex-smoker 1,395 (27.8) 499 (27.9)
Current smoker 2,023 (40.4) 834 (46.6)
Alcohol intake 0.25
Frequent drinker 2,250 (44.9) 775 (43.3)
Infrequent drinker 2,761 (55.1) 1,014 (56.7)
Diabetes mellitus 100 (2.0) 79 (4.4) <0.001
Hypertension 618 (12.3) 298 (16.7) <0.001
FPG (mg/dL) 96.70 (13.0) 99.53 (18.59) <0.001
SBP (mm Hg) 114.69 (14.10) 116.82 (14.76) <0.001
ALT (mg/dL) 27.26 (11.60) 31.51 (13.84) <0.001
Chol/HDL ratio 3.91 (0.87) 4.22 (0.89) <0.001
Total bilirubin (μmol/L)  17.82 (5.29) 16.78 (4.99) 0.03
Values are presented as mean (SD) or number (%).
BMI: body mass index calculated as weight in kilograms divided by 
height in meters squared, FPG: fasting plasma glucose, SBP: 
systolic blood pressure, ALT: alanine aminotransferase, Chol/HDL 
ratio: total cholesterol/ high density lipoprotein-cholesterol ratio.
*P-value from a t-test for continuous outcomes and χ
2 test for 
binary outcomes comparing a difference between the 2 study 
groups.Kiwoong Yu, et al: Association of Bilirubin with C-reactive Protein
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Table 2. Mean and prevalence (%) of baseline variables according to quartiles of total bilirubin (μmol/L). 
1st quartile
≤13.85
(n = 1,668)
2nd quartile
13.86-16.76
(n = 1,678)
3rd quartile
16.77-20.69
(n = 1,750)
4th quartile
≥20.70
(n = 1,704)
P-value*
Age
† (y) 44.31 (3.95) 44.24 (3.76) 44.04 (3.50) 44.09 (3.74) <0.001
BMI
‡ (kg/m
2) 24.51 (2.54) 24.32 (2.50) 24.40 (2.55) 24.23 (2.54) 0.01
Smoking status
§   <0.001
Non-smoker 414 (24.8) 463 (27.6) 579 (33.1) 576 (33.8)
Ex-smoker 400 (24.0) 472 (28.1) 523 (29.9) 498 (29.2)
Current smoker 854 (51.2) 743 (44.3) 648 (37.0) 630 (37.0)
Alcohol intake 0.67
Frequent drinker 887 (53.2) 972 (57.9) 989 (56.5) 929 (54.5)
Infrequent drinker 781 (46.8) 706 (42.1) 761 (43.5) 775 (45.5)
Diabetes mellitus 38 (2.3) 44 (2.6) 51 (2.9) 46 (2.7) 0.45
Hypertension 212 (12.7) 221 (13.2) 236 (13.5) 245 (14.4) 0.14
FPG (mg/dL) 97.21 (12.64) 97.48 (14.63) 97.25 (14.80) 97.45 (14.73) 0.59
SBP (mm Hg) 114.73 (13.99) 115.38 (14.20) 115.04 (14.60) 115.85 (14.38) 0.13
ALT (mg/dL) 28.86 (12.48) 28.41 (12.21) 28.17 (12.31) 28.08 (12.50) 0.26
Chol/HDL ratio
§ 4.04 (0.87) 4.01 (0.89) 3.97 (0.88) 3.94 (0.89) 0.01
hsCRP
∥ (mg/L) 0.92 (0.91) 0.83 (0.82) 0.76 (0.75) 0.73 (0.74) <0.001
Values are presented as mean (SD) or number (%).
BMI: body mass index calculated as weight in kilograms divided by height in meters squared, FPG: fasting plasma glucose, SBP: systolic 
blood pressure, ALT: alanine aminotransferase, Chol/HDL ratio: total cholesterol/high density lipoprotein-cholesterol ratio.
*P-value from an ANOVA test for continuous outcomes and χ
2 test for binary outcomes comparing differences among 4 study groups. 
Turkey HSD used for Post Hoc analysis. 
†Statistically different between 1st quartile, 2nd quartile vs. 3rd quartile, 4th quartile. 
‡Statistically 
different between 1st quartile vs. 4th quartile. 
§Statistically different between 1st quartile vs. 2nd quartile vs. 3rd quartile, 4th quartile. 
∥Statistically different between 1st quartile vs. 2nd quartile, 3rd quartile, 4th quartile and 2nd quartile vs. 4th quartile.
Table 3. Adjusted odds ratios (aOR) and 95% confidence intervals (CI) of increased hsCRP by quartiles of total bilirubin. high density 
lipoprotein.  
Total bilirubin (μmol/L)
aOR and 95% CI of increased hsCRP
Model I Model II Model III
≤13.85 1 1 1
13.86-16.76 0.82 (0.70-0.95) 0.82 (0.71-0.96) 0.83 (0.71-0.97)
16.77-20.69 0.73 (0.63-0.85) 0.75 (0.65-0.88) 0.76 (0.65-0.89)
≥20.70 0.61 (0.52-0.71) 0.63 (0.54-0.74) 0.64 (0.55-0.75)
P-value for trend <0.001 <0.001 <0.001
Values are presented as adjusted odds ratio (95% CI). 
Increased high sensitivity C-reactive protein (hsCRP): categorization of hsCRP as < 1.0 mg/L and ≥ 1.0 mg/L. 
Model I: age-adjusted odds ratio, Model II: adjusted for age, smoking status, drinking frequency, Model III: body mass index, alanine 
aminotransferase, fasting plasma glucose, systolic blood pressure, total cholesterol/high density lipoprotein-cholesterol ratio are added to 
Model II. Kiwoong Yu, et al: Association of Bilirubin with C-reactive Protein
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model II), when compared to the lowest quartile of serum total 
bilirubin, the ORs (95% CI) for hsCRP in the 2nd, 3rd, and 4th 
sTB quartiles signifi  cantly decreased (all P for trend < 0.001).
DISCUSSION
In this study, hsCRP was inversely associated with sTB. In 
addition, hsCRP had signifi  cant positive associations with BMI; 
smoking status; medical history of DM and HT; and levels of 
systolic BP, FPG, ALT, and the TC/HDL-C ratio, but was not 
associated with age or alcohol consumption. 
Serum bilirubin is known to have an antioxidant effect and 
an inverse relationship with the risk for CVD.
11-14) Bilirubin is 
a final metabolite of heme, but the function of bilirubin is not 
clear. Vitek et al.
15) reported that patients with Gilbert syndrome, 
who have a slightly elevated level of serum direct bilirubin, had 
a lower risk of CVD compared to healthy subjects. According to 
the NHANES study (1999-2004),
13) a 1.71 micromol/L (0.1 
mg/dL) increment in bilirubin level was associated with a 9% 
reduction in the odds of stroke (OR, 0.91; 95% CI, 0.86 to 0.96) 
among the civilian population and with a 10% reduction in the 
odds of stroke (OR, 0.90; 95% CI, 0.80 to 1.00) among patients 
with a history of stroke. Nobotny and Vitek
14) reported that serum 
bilirubin in men had an inverse relationship with the severity of 
AS in a meta-analysis of 11 studies. We found that aft  er adjusting 
for other risk factors of CVD, sTB was inversely associated with 
hsCRP, which is a predictive indicator for CVD, and this fi  nding 
is consistent with the results of previous studies. Although this 
was a cross-sectional study and our participants were middle-aged 
Korean men who visited a health promotion center, we believe 
the number of study participants was sufficient to evaluate the 
relationship between sTB and hsCRP. 
There have been several studies about the relationship 
between hsCRP and risk factors for CVD. Nakanishi et al.
16) 
reported that hsCRP had a significant relationship with age, 
smoking status, serum fasting glucose, BMI, BP, HDL-C, and 
triglycerides. In a previous Korean study,
17) hsCRP had a positive 
relationship with serum fasting glucose, age, and BP. However, 
hsCRP was not signifi  cantly associated with age in our study. Th  is 
result is possibly due to the narrow age distribution of our study 
sample (40 to 59 years old). 
Mild to moderate alcohol consumption reduces hsCRP. 
Several studies
18-20) reported that men who drank one to four 
drinks of alcoholic beverages per week had the lowest levels 
of hsCRP, and the relationship between alcohol consumption 
and hsCRP was U shaped. However, this study did not detect a 
signifi  cant association between alcohol consumption and hsCRP. 
We did not collect specific information about the amount of 
alcohol consumed by study subjects because of our inability to 
validate the information. Serum bilirubin is affected by aging, 
smoking status, and fasting state, among other factors, and has 
an inverse relationship with risk factors for CVD, such as aging, 
obesity, smoking, HT, and dyslipidemia.
7,21,22) We found that 
sTB had an inverse association with age, BMI, smoking status, 
and the TC/HCL-C ratio. However, in this study, sTB did not 
demonstrate a significant relationship with HT or systolic BP. 
A previous Korean study
23) reported that serum bilirubin had 
a significant relationship with HT in women but not in men. 
Therefore, we suggest that future studies about the association 
between sTB and BP or HT in the general population should 
include women and older people. 
We transformed the levels of sTB measured in this study 
to SI units (μmol/L). The SI unit for sTB levels contains more 
information and is bett  er at detecting changes of serum bilirubin 
within physiologic levels.
14)
However, further studies about the relationships between 
other forms of serum bilirubin and risk factors for CVD are 
necessary. It is not clear how serum bilirubin lowers the risk of 
CVD. One potential mechanism is the antioxidant and anti-
infl  ammatory eff  ects of bilirubin through inhibition of oxidation 
of low-density lipoprotein cholesterol (LDL-C) and oxygen 
radicals, which may consequently prevent AS. Another possible 
mechanism is the association of high-density serum bilirubin 
with lower levels of infl  ammation.
24-26)
One of the limitations of this study was that we included only 
the total level of serum bilirubin in the analysis to investigate the 
association with hsCRP and risk factors for CVD; serum direct 
and indirect bilirubin were not included in the analysis. Because all 
forms of bilirubin (free or albumin-bound) inhibit hyperoxidation 
of LDL-C,
27) this limitation might not have aff  ected our results. 
Th   e other limitation was the age distribution of the study sample. 
Th   e study subjects were middle-aged Korean men (40-59 years 
old); therefore, the results may not be necessarily generalized to Kiwoong Yu, et al: Association of Bilirubin with C-reactive Protein
332  |  Vol. 32, No. 6 Sep 2011 Korean J Fam Med
other populations in or outside of Korea. Th   e third limitation was 
that this study was a cross-sectional study, which makes it diffi   cult 
to detect a causal relationship between sTB and hsCRP and risk 
factors for CVD. 
In conclusion, this study showed that sTB was inversely 
associated with hsCRP and risk factors for CVD. Despite some 
limitations, this study is meaningful because it is a large study of 
subjects who visited a health promotion center. We anticipate that 
the results of this study will be used in future studies. 
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